Patients with high risk of disease recurrence after curative resection for hepatocellular
carcinoma (HCC) deserve active intervention. However, there's limited treatment choice for
these patients. Anlotinib hydrochloride, a multitarget tyrosine kinase inhibitor for both
tumor angiogenesis and proliferative signaling in cancer cells, is approved in China for the
3rd line treatment of advanced non-small cell lung cancer. In the current study, we are to
evaluate the safety and effects of adjuvant anlotinib therapy for the patients who underwent
curative resection for HCC with high risk of tumor recurrence, which is defined by Shanghai
Score (Sun, et al. Chin Med J (Engl) 2017).